Spago Nanomedical AB (FRA:7UX) Interest Expense : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Spago Nanomedical AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Spago Nanomedical AB's interest expense for the three months ended in Mar. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Spago Nanomedical AB's Operating Income for the three months ended in Mar. 2024 was € -0.71 Mil. Spago Nanomedical AB's Interest Expense for the three months ended in Mar. 2024 was € 0.00 Mil. Spago Nanomedical AB has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Spago Nanomedical AB Interest Expense Historical Data

The historical data trend for Spago Nanomedical AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Interest Expense Chart

Spago Nanomedical AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Spago Nanomedical AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Spago Nanomedical AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Spago Nanomedical AB (FRA:7UX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Spago Nanomedical AB's Interest Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-0.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €0.00 Mil.

Spago Nanomedical AB's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Spago Nanomedical AB had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Spago Nanomedical AB has no debt.

Spago Nanomedical AB (FRA:7UX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (FRA:7UX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SPAGO:Sweden

Address

Scheelevagen 22, Lund, SWE, SE-223 63

Website

https://www.spagonanomedical.se

Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (FRA:7UX) Headlines

No Headlines